Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Maxim Group

Maxim Group upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) from a hold rating to a buy rating in a research note released on Friday morning,Benzinga reports. The brokerage currently has $7.00 target price on the stock.

Several other brokerages have also recently commented on RVPH. EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Roth Mkm started coverage on Reviva Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $7.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $11.25.

Reviva Pharmaceuticals Stock Up 0.5 %

Shares of RVPH stock opened at $1.88 on Friday. Reviva Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $4.83. The company’s fifty day simple moving average is $1.56 and its 200-day simple moving average is $1.29. The firm has a market cap of $62.87 million, a PE ratio of -1.69 and a beta of -0.12.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 278,496 shares of the company’s stock after buying an additional 42,376 shares during the period. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.